You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Ovarian cancer using novel nanoparticle formulations
SBC: KIROMIC BIOPHARMA INC Topic: 102DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
High Spatial Resolution Ultrafast Sum-Frequency Generation Microscope
SBC: PHYSICS, MATERIALS, AND APPLIED MATHEMATICS RESEARCH L.L.C. Topic: 07aVibrationally resonant sum-frequency generation (SFG) spectroscopy is a second order nonlinear optical technique that features high chemical selectivity and a set of selection rules that makes it an ideal complement to coherent Raman scattering (CRS) as an imaging tool. Attempts have been made to construct high-resolution, high speed SFG microscopes, but to date both the resolving power and image ...
STTR Phase I 2014 Department of Energy -
Uniform, High Intensity X-ray Source for Blood Irradiation
SBC: National Nanomaterials, Inc Topic: 22aThere is an ongoing effort to replace high activity radioactive sources that could pose a risk for use as terrorist weapons with non-radioisotope based technologies. Currently radioactive sources serve a number of critical needs including the treatment and diagnosis of disease, inspection and certification of critical mechanical structures, the sterilization of food and medical products, ...
STTR Phase I 2014 Department of Energy -
Next Generation Semiconductor-Based Radiation Detectors Using Cadmium Magnesium Telluride
SBC: BRIMROSE TECHNOLOGY CORP Topic: 23cAt present, CdZnTe is considered the material of choice for efficient, room temperature gamma-radiation detection systems used for the detection and identification of radionuclides. Despite the advances in CdZnTe materials technology during the last decade, the major impediments in the progress of - ray detection technology are the low yield of device quality materials and detectors, and the limit ...
STTR Phase I 2014 Department of Energy -
VALIDATION OF FLUORESCENT DEOXYGLUCOSE (2-NBDG) IN TUMORS
SBC: 3GEN, LLC Topic: N/ADESCRIPTION (provided by applicant): A new fluorescent analogue of d-glucose, 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2- deoxyglucose (2-NBDG), was recently developed, but has not been characterized as a marker of glucose uptake in cancer cells. Validating this new tracer as a glucose analogue for optical imaging of superficial tumors may have a major impact on clinical and preclinical imag ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Auto-antibody profiling of non-small cell lung cancer
SBC: 20 20 Genesystems Inc Topic: N/ADESCRIPTION (provided by applicant): Tumor markers, measured in peripheral blood, could assist in diagnosis and management of non-small cell lung cancer (NSCLC) and potentially improve historically dismal outcomes. Circulating antibodies, generated to a wide range of tumor-associated proteins, can be translated into a valuable blood test for lung cancer. Preliminary data supports this hypothesis. ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Oral Formulation of Zonulin Antagonist AT-1001 for Diabe
SBC: ALBA THERAPEUTICS CORPORATION Topic: N/ADESCRIPTION (provided by applicant): The trigger for autoimmune destruction of pancreatic beta cells in Type 1 diabetes (T1D) is unclear. Evidence exists for the role of increased intestinal permeability, secondary to intestinal tight junctions (tj) disassembly, in the pathogenesis of various autoimmune diseases including T1 D. Over the last decade our studies have focused on the mechanism(s) of a ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Parallel DNA Assembling on MicroChip
SBC: ATACTIC TECHNOLOGIES, INC. Topic: N/ADESCRIPTION (provided by applicant): The increasing use of DNA as a molecular tool has ushered the technology of de novo synthesis of DNA back to the center stage of modern biology. We propose the development of a robust, ultra high-throughput (UHT) technology capable of genome-scale production of high fidelity synthetic DNA at about one percent of the cost and time of the current technologies. Ou ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health